Key Financials Snapshot

TTM · Standalone · ₹ in Cr
Market Cap
₹127 Cr.
Stock P/E
10.8
P/B
1
Current Price
₹62.5
Book Value
₹ 62.4
Face Value
10
52W High
₹86.5
52W Low
₹ 37.8
Dividend Yield
—

Sheel Biotech Overview

Business

Sheel Biotech Ltd. is an Indian agricultural biotechnology company focused on providing advanced inputs for sustainable farming. Its core business involves the production and marketing of a diverse range of high-quality products, including:

Tissue Culture Plants: Micro-propagated plants for various categories such as fruits (e.g., banana, pomegranate), forestry, ornamental, and medicinal plants, ensuring disease-free and genetically uniform planting material.

Bio-inputs: Manufacturing and distribution of eco-friendly bio-fertilizers and bio-pesticides to enhance soil health and crop protection while reducing chemical reliance.

Seeds: Development, processing, and sale of high-quality seeds for various agricultural crops.

The company makes money by selling these specialized agri-biotech products directly to farmers, nurseries, and through its distribution network, aiming to improve crop yield, quality, and farm profitability.

Revenue Mix

While Sheel Biotech Ltd. does not consistently provide a precise revenue breakdown by segment in its public reports, its operations are primarily centered around three main product categories:

Tissue Culture: This segment involves the propagation of plants using biotechnology, a significant focus area given their infrastructure.

Bio-inputs: Comprising bio-fertilizers and bio-pesticides.

Seeds: Including a variety of crop seeds.

These segments collectively contribute to the company's revenue, offering an integrated approach to agricultural inputs.

Industry

Sheel Biotech operates within the broad and vital Indian agriculture sector, specifically targeting the growing segments of agricultural biotechnology, bio-inputs, and quality seeds. The Indian agri-input industry is highly competitive, featuring large multinational corporations (e.g., Syngenta, Bayer) and major Indian players in traditional fertilizers and pesticides, alongside several specialized biotech firms. Sheel Biotech positions itself as a provider of advanced, environmentally friendly, and high-quality biotech solutions. It competes based on its R&D capabilities, particularly in tissue culture, and the efficacy and quality of its specialized products, serving a market increasingly valuing sustainable agricultural practices.

MOAT

Sheel Biotech's competitive advantages are primarily derived from:

Technical Expertise & R&D: Deep expertise in tissue culture technology, which allows for the production of disease-free, high-yielding, and genetically uniform planting material – a specialized and difficult-to-replicate process.

Diversified Sustainable Portfolio: Offering a combination of tissue culture plants, bio-fertilizers, bio-pesticides, and quality seeds provides a comprehensive and sustainable solution, catering to evolving farmer preferences.

Niche Market Focus: By specializing in certain biotech solutions, the company can build a reputation for quality and efficacy within specific product categories or regional markets.

Established Infrastructure: An operational network of tissue culture labs and processing units supports its production capabilities.

Growth Drivers

Government Support for Sustainable Agriculture: Indian government initiatives promoting organic farming, reducing chemical use, and enhancing farmer income directly boost demand for bio-inputs and quality planting material.

Increasing Farmer Awareness & Adoption: Growing education and awareness among farmers about the benefits of advanced agricultural inputs like tissue culture and bio-fertilizers for better yields and resilience.

Technological Advancements: Continuous investment in R&D to develop new, improved plant varieties and more effective bio-inputs tailored to specific regional needs and environmental challenges.

Market Expansion: Opportunities to expand its distribution network and product reach into new geographical markets within India and potentially internationally.

Climate Change Adaptation: Demand for climate-resilient, disease-resistant, and high-yielding crop varieties, which biotech solutions can effectively provide.

Risks

Monsoon Dependency: The financial performance of Sheel Biotech is highly susceptible to the vagaries of the Indian monsoon, which directly impacts agricultural output and farmer demand for inputs.

Intense Competition: Faces significant competition from larger, well-established national and multinational players with greater financial resources, extensive distribution networks, and strong brand recognition.

Regulatory Changes: Changes in agricultural policies, seed laws, or biotechnology regulations by the Indian government could impact product approvals, market access, and operational costs.

R&D Success: Reliance on successful research and development for new product innovation; R&D failures can be costly and impact future growth.

Price Volatility of Raw Materials: Fluctuations in the cost of raw materials required for bio-fertilizers or growth media for tissue culture can affect profitability.

Pest & Disease Outbreaks: Unexpected outbreaks can severely damage crops, affecting farmer incomes and, consequently, demand for agri-inputs.

Management & Ownership

Sheel Biotech Ltd. is promoted by the Sahoo family, with Mr. Pravat Kumar Sahoo serving as the Managing Director, providing leadership and strategic direction. The promoters generally hold a significant equity stake in the company, a common characteristic in many Indian small and medium-sized enterprises (SMEs). This high promoter holding often signifies a strong alignment between the interests of the management and long-term shareholders. The management team brings experience in the agricultural and biotechnology sectors.

Outlook

Sheel Biotech operates in a promising, albeit competitive, segment of the Indian agricultural sector. The growing emphasis on sustainable agriculture, organic farming, and improving farm productivity in India provides a favorable environment for its specialized biotech products. The company's focus on tissue culture and bio-inputs aligns well with these national priorities, and its technical expertise presents a foundational strength. However, Sheel Biotech, as a relatively smaller player, must contend with intense competition from larger, more entrenched players and the inherent seasonality and monsoon dependency of the agricultural sector. Future success will largely depend on its ability to continually innovate through R&D, expand its market reach effectively, manage regulatory complexities, and maintain cost efficiency while delivering high-quality, impactful products to the farming community.

Sheel Biotech Share Price

Live · NSE · Inception: 1991
₹ | |
Volume
Price

Key Financials — Profit & Loss

₹ in Cr · Standalone · annual

Sheel Biotech Quarterly Results

#(Fig in Cr.)
Net Sales
Other Income
Total Income
Total Expenditure
Operating Profit
Interest
Depreciation
Exceptional Income / Expenses
Profit Before Tax
Provision for Tax
Profit After Tax
Adjustments
Profit After Adjustments
Adjusted Earnings Per Share

Sheel Biotech Profit & Loss

#(Fig in Cr.) Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 TTM
Net Sales 70 71 60 61 61 63 71 80 92 102 110
Other Income 0 0 0 0 0 0 0 0 0 1 1
Total Income 70 71 61 61 61 63 71 80 93 102 111
Total Expenditure 62 63 53 53 54 57 64 71 78 87 94
Operating Profit 8 8 8 8 7 7 7 9 15 15 17
Interest 1 1 1 1 2 1 1 2 1 2 2
Depreciation 1 1 1 1 1 1 1 1 1 1 1
Exceptional Income / Expenses 0 0 0 0 0 0 0 0 0 0 0
Profit Before Tax 6 6 6 6 4 5 5 6 12 13 14
Provision for Tax 0 0 0 0 0 0 0 1 2 2 2
Profit After Tax 6 5 5 6 4 5 5 5 10 11 12
Adjustments 0 0 0 0 0 0 0 0 0 0 0
Profit After Adjustments 6 5 5 6 4 5 5 5 10 11 12
Adjusted Earnings Per Share 3.8 3.8 3.7 4.4 3 3.3 3.1 3.5 7.2 7.2 5.8

Sheel Biotech Balance Sheet

#(Fig in Cr.) Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Shareholder's Funds 35 39 44 49 53 57 60 64 73 84 127
Minority's Interest 0 0 0 0 0 0 0 0 0 0 0
Borrowings 1 0 1 4 8 12 13 9 10 5 1
Other Non-Current Liabilities 0 0 0 0 0 0 0 0 0 1 0
Total Current Liabilities 23 27 16 17 21 13 20 21 23 22 17
Total Liabilities 59 67 61 70 81 82 93 94 106 111 146
Fixed Assets 8 8 8 8 8 8 8 8 7 7 9
Other Non-Current Assets 0 0 0 0 1 1 2 3 3 5 8
Total Current Assets 51 59 53 63 72 74 83 83 95 99 128
Total Assets 59 67 61 70 81 82 93 94 106 111 146

Sheel Biotech Cash Flow

#(Fig in Cr.) Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Opening Cash & Cash Equivalents 0 0 0 0 0 0 0 0 0 1 0
Cash Flow from Operating Activities 2 4 -1 0 -0 0 2 9 -1 9 -18
Cash Flow from Investing Activities -1 -0 -1 -0 -1 0 -2 -2 -0 -2 -7
Cash Flow from Financing Activities -1 -4 1 -0 2 0 -0 -7 2 -6 26
Net Cash Inflow / Outflow 0 0 -0 0 0 0 -0 -0 0 -0 2
Closing Cash & Cash Equivalent 0 0 0 0 0 0 0 0 1 0 2

Sheel Biotech Ratios

# Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Earnings Per Share (Rs) 3.84 3.78 3.71 4.43 3.05 3.31 3.11 3.5 7.22 7.19 5.78
CEPS(Rs) 4.45 4.24 4.16 4.86 3.57 3.83 3.76 4.2 7.9 7.79 6.3
DPS(Rs) 0.57 0.57 0.57 0.57 0.57 0.53 0.89 0.89 0.89 1 0
Book NAV/Share(Rs) 24.11 27.2 30.23 33.97 36.32 39.1 41.2 43.81 50.12 56.09 62.4
Core EBITDA Margin(%) 11.49 11.24 12.29 13.54 10.85 10.31 9.02 11.02 15.66 14.71 14.8
EBIT Margin(%) 10.38 10.45 11.44 12.64 9.9 9.46 8.16 9.85 14.88 14.34 14.48
Pre Tax Margin(%) 8.59 8.46 9.51 10.59 7.32 7.61 6.49 7.95 13.28 12.6 12.74
PAT Margin (%) 7.94 7.76 8.9 10.57 7.25 7.61 6.38 6.34 11.35 10.57 10.69
Cash Profit Margin (%) 9.21 8.72 9.97 11.61 8.49 8.81 7.71 7.61 12.42 11.45 11.65
ROA(%) 9.99 8.7 8.46 9.81 5.83 5.86 5.14 5.43 10.49 9.91 9.15
ROE(%) 17.02 14.73 12.93 13.8 8.67 8.77 7.75 8.24 15.38 13.74 11.15
ROCE(%) 17.14 15.81 13.37 12.98 9.07 8.05 7.16 9.5 15.35 14.78 13.43
Receivable days 179.56 230.75 288.35 293.5 328.95 339.04 323.52 275.07 224.95 202.28 193.88
Inventory Days 46.61 34.02 28.43 30.47 40.63 42.74 46.71 70.91 102.98 129.42 114.37
Payable days 60.47 49.75 48.26 38.45 61.88 64.57 45.45 56.91 40.99 30.14 25.83
PER(x) 0 0 0 0 0 0 0 0 0 0 6.92
Price/Book(x) 0 0 0 0 0 0 0 0 0 0 0.64
Dividend Yield(%) 0 0 0 0 0 0 0 0 0 0 0
EV/Net Sales(x) 0.2 0.18 0.26 0.29 0.35 0.39 0.39 0.29 0.29 0.31 0.8
EV/Core EBITDA(x) 1.74 1.56 2.07 2.13 3.16 3.7 4.08 2.59 1.84 2.06 5.19
Net Sales Growth(%) 3.68 0.72 -14.35 0.49 0.31 3.41 12.23 13.26 15.19 10.26 8.13
EBIT Growth(%) 10.71 1.37 -6.19 11.01 -21.41 -1.21 -3.21 36.71 74.02 6.25 9.19
PAT Growth(%) 13.9 -1.48 -1.8 19.34 -31.2 8.55 -5.99 12.56 106.34 2.68 9.31
EPS Growth(%) 13.9 -1.48 -1.8 19.34 -31.2 8.55 -5.99 12.56 106.34 -0.41 -19.69
Debt/Equity(x) 0.29 0.22 0.26 0.28 0.33 0.37 0.39 0.3 0.32 0.21 0.07
Current Ratio(x) 2.19 2.18 3.27 3.59 3.48 5.52 4.25 4.04 4.22 4.49 7.53
Quick Ratio(x) 1.82 2.02 2.96 3.3 3.07 5.05 3.65 3.1 2.77 2.71 5.79
Interest Cover(x) 5.78 5.25 5.92 6.15 3.83 5.12 4.9 5.19 9.28 8.26 8.32
Total Debt/Mcap(x) 0 0 0 0 0 0 0 0 0 0 0.11

Growth Rates

Compounded annual
# 1 Year 3 Year 5 Year 10 Year
Sales CAGR +8% +11% +12% +5%
Operating Profit CAGR +13% +24% +19% +8%
PAT CAGR +9% +34% +19% +7%
Share Price CAGR -24% — — —
ROE Average +11% +13% +11% +12%
ROCE Average +13% +15% +12% +12%

Sheel Biotech Shareholding Pattern

Latest · Sep 2026
100% held
Promoters 72.31 %
FII 0 %
DII (MF + Insurance) 9.66 %
Public (retail) 18.03 %
# Mar 2026 Sep 2026
Promoter 72.2972.31
FII 00
DII 9.499.66
Public 18.2218.03
Others 00
Total 100100

Sheel Biotech Peer Comparison

Agriculture Edit Columns

Sheel Biotech Quarterly Price

10-year quarterly close · BSE
Show Value Show %

News & Updates

See more…

Sheel Biotech Pros & Cons

Pros

  • Debtor days have improved from 30.14 to 25.83days.
  • Company has reduced debt.
  • Company is almost debt free.

Cons

  • Company has a low return on equity of 13% over the last 3 years.
Want to Start Investing in Top Unlisted Stocks?

Our experts help you choose the right stocks based on performance, risk, and growth potential.

whatsapp